Zobrazeno 1 - 10
of 162
pro vyhledávání: '"Joel F, Farley"'
Autor:
Arun Kumar, Pamela L. Lutsey, Wendy L. St. Peter, Jon C. Schommer, Jeremy R. Van’t Hof, Abhijeet Rajpurohit, Joel F. Farley
Publikováno v:
Clinical and Translational Science, Vol 16, Iss 10, Pp 1886-1897 (2023)
Abstract P2Y12 inhibitors (i.e., clopidogrel, prasugrel, or ticagrelor) are effective at reducing adverse cardiovascular outcomes post‐revascularization in coronary artery disease (CAD). However, the choice of a specific P2Y12 inhibitor may vary ac
Externí odkaz:
https://doaj.org/article/e002a9f3ca84407dbaaec17fcc20257e
Publikováno v:
Therapeutic Advances in Drug Safety, Vol 14 (2023)
Background: Logistic regression-based signal detection algorithms have benefits over disproportionality analysis due to their ability to handle potential confounders and masking factors. Feature exploration and developing alternative machine learning
Externí odkaz:
https://doaj.org/article/66fbfce2df0a4dc5ae02739a210ab539
Autor:
Pamela L. Lutsey, Line H. Evensen, Thenappan Thenappan, Kurt W. Prins, Rob F. Walker, Joel F. Farley, Richard F. MacLehose, Alvaro Alonso, Neil A. Zakai
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 11, Iss 14 (2022)
Background Pulmonary hypertension (PH) is a devastating potential complication of pulmonary embolism, a manifestation of venous thromboembolism (VTE). The incidence of and risk factors for PH in those with prior VTE are poorly characterized. Methods
Externí odkaz:
https://doaj.org/article/ee6b78bab45543bcac7ae76fcf308c3f
Autor:
Susan J. Blalock, Chelsea P. Renfro, Jessica M. Robinson, Joel F. Farley, Jan Busby-Whitehead, Stefanie P. Ferreri
Publikováno v:
BMC Geriatrics, Vol 20, Iss 1, Pp 1-8 (2020)
Abstract Background The Drug Burden Index (DBI) was developed to assess patient exposure to medications associated with an increased risk of falling. The objective of this study was to examine the association between the DBI and medication-related fa
Externí odkaz:
https://doaj.org/article/680be86fb5f042c5a5b9c6282747e427
Publikováno v:
Exploratory Research in Clinical and Social Pharmacy, Vol 4, Iss , Pp 100089- (2021)
Background: As a result of COVID-19, numerous adaptations were made to health care delivery, including comprehensive medication management (CMM) delivered in community pharmacies. Objective: Identify and describe the adaptations that have been made t
Externí odkaz:
https://doaj.org/article/fd3844dcf10d44e6ac0543088d6c7adf
Autor:
Justin G Trogdon, Krutika Amin, Parul Gupta, Benjamin Y Urick, Katherine E Reeder-Hayes, Joel F Farley, Stephanie B Wheeler, Lisa Spees, Jennifer L Lund
Publikováno v:
PLoS ONE, Vol 16, Iss 11, p e0260358 (2021)
BackgroundWe conducted a mediation analysis of the provider team's role in changes to chronic condition medication adherence among cancer survivors.MethodsWe used a retrospective, longitudinal cohort design following Medicare beneficiaries from 18-mo
Externí odkaz:
https://doaj.org/article/bcafc9db25ae4b6680b74dfb633e9098
Autor:
Arun Kumar, Pamela L. Lutsey, Wendy L. St. Peter, Jon C. Schommer, Jeremy R. Van't Hof, Abhijeet Rajpurohit, Joel F. Farley
Publikováno v:
Clinical Pharmacology & Therapeutics. 113:412-422
In closely monitored randomized controlled trials (RCTs), newer P2Y12 agents (ticagrelor and prasugrel) reduced cardiovascular outcomes compared to clopidogrel following percutaneous coronary intervention (PCI) in acute coronary syndrome (ACS). Howev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17cc9e6c7589fd4737b6bdc8d64ac2f9
https://doi.org/10.1002/cpt.2806
https://doi.org/10.1002/cpt.2806
Autor:
Arun Kumar, Pamela L. Lutsey, Wendy L. St Peter, Jon C. Schommer, Jeremy R. Van't Hof, Abhijeet Rajpurohit, Joel F. Farley
Publikováno v:
Clinical Pharmacology & Therapeutics. 113:401-411
Comparative effectiveness evaluation of newer P2Y12 inhibitors (prasugrel and ticagrelor) compared to clopidogrel after acute coronary syndrome (ACS) is limited in real-world US populations. The objective of this study was to evaluate cardiovascular
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ebc4f3c7fbf5a51fad6893b4aa949bb
https://doi.org/10.1002/cpt.2797
https://doi.org/10.1002/cpt.2797
Autor:
Kea Turner, Justin G. Trogdon, Morris Weinberger, Angela M. Stover, Stefanie Ferreri, Joel F. Farley, Neepa Ray, Michael Patti, Chelsea Renfro, Christopher M. Shea
Publikováno v:
Implementation Science, Vol 13, Iss 1, Pp 1-13 (2018)
Abstract Background Many state Medicaid programs are implementing pharmacist-led medication management programs to improve outcomes for high-risk beneficiaries. There are a limited number of studies examining implementation of these programs, making
Externí odkaz:
https://doaj.org/article/63eaf547b49348c0a81618b5af9315a4
Autor:
Arun Kumar, Ashna Talwar, Joel F. Farley, Jagannath Muzumdar, Jon C. Schommer, Rajesh Balkrishnan, Wenchen Wu
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 8, Iss 10 (2019)
Background Fondaparinux sodium has been compared with low‐molecular‐weight heparins (LMWH) in randomized controlled trials for perioperative surgical thromboprophylaxis. However, the results from these studies are inconsistent in terms of efficac
Externí odkaz:
https://doaj.org/article/68821db4f615476aac8b239d14e7b17d